Incyte gets green light for new eczema cream – and a warning

A topical version of Incyte's eczema drug ruxolitnib has passed through the eye of the needle at the FDA, but a warning has been issued regarding its drug class.

Photo: Andrew Kelly/REUTERS / X02844

After an extended assessment period, the FDA has ruled on Incyte's topical formulation of eczema treatment ruxolitnib.

The authority has approved the treatment for use in atopic dermatitus (commonly known as eczema). The cream will be marketed under the name of Opzelura, while the first version, which is administered in tablet form, is called Jakavi or Jakafi, depending on the market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs